Despite the central role of the PPAR/PGC1α pathway in AKI, a recent clinical study of the PPARδ agonist ASP1128 did not show significant renal beneficial effects on reducing AKI incidence or severity after major cardiac surgery as expected (van Till et al., 2023). The gene discussed is PPARGC1A; the disease is acute kidney injury.